Malignant Ovarian Neoplasm — Trials

Malignant Ovarian Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 684
Recruiting: 385
Ph III recruiting: 46
Growth YoY: +9.8%
Industry share: 37%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.8%
Trials / 1,000 deaths: 53.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (437)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03079687	Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.	approved for marketing	—	—	AstraZenecaINDUSTRY	1	Oct 25, 2017	clinicaltrials
NCT03025867	Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer	approved for marketing	—	—	Tesaro, Inc.INDUSTRY	0	Apr 17, 2017	clinicaltrials